
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [1][3]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives made false and misleading statements regarding the company's competitive position and financial guidance [3]. - Specifically, it is claimed that LifeMD's 2025 guidance was raised recklessly without properly accounting for increased customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs [3]. - As a result of these alleged misstatements, the company's business operations and prospects were deemed materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous estimate of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].